Business Context and Reporting Period
This Form 8-K was filed by Tivic Health Systems, Inc. (TIVC) on May 14, 2025, reporting an event that occurred on May 9, 2025. The filing discloses the entry into a Material Definitive Agreement with Scorpius BioManufacturing, Inc. to serve as the primary U.S. manufacturer for Tivic's late-stage TLR5 agonist, Entolimod, which is intended for the treatment of acute radiation syndrome.
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins). The primary financial data relates to the new manufacturing agreement:
- Estimated Service Fees: Approximately $2.4 million.
- Total Estimated Investment: Approximately $4.1 million (inclusive of pass-through costs for consumables, raw materials, and external services).
- Administrative Fee: Pass-through costs are managed at cost plus a 15% administrative fee.
- Payment Terms: Invoices are payable within 30 days; late payments incur 1% monthly interest.
Material Changes and Agreement Terms
The material change is the execution of a Statement of Work with Scorpius BioManufacturing. Key operational and contractual terms include:
- Scope of Services: Cell line verification, legacy process verification, GMP scale-up production, drug product fill and finish, analytical development, and process optimization.
- Intellectual Property: Tivic will own all deliverables and foreground intellectual property generated specifically for Entolimod.
- Termination: Either party may terminate with 60 days' written notice. Termination requires payment of open invoices, documented wind-down expenses, and liquidated damages equal to the greater of 50% of unperformed costs or 75% of prices for services scheduled within 60 days of termination.
Outlook, Risks, and Management Commentary
Management has issued a press release (Exhibit 99.1) regarding the agreement. The filing includes standard forward-looking statements warning that actual results may differ materially from estimates due to risks and uncertainties. Specific risks include the potential for actual costs to exceed estimates and the general risks associated with drug development and manufacturing partnerships. The filing explicitly states that the information is not "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings except as expressly stated.
Investor Verification Checklist
- Verify the total capital requirements for the Entolimod manufacturing program, noting the $4.1 million estimated investment.
- Review the full text of the Statement of Work (to be filed as an exhibit in the next periodic report) for detailed milestone definitions.
- Assess the impact of the 15% administrative fee on pass-through costs and the potential for cost overruns.
- Monitor the company's cash position to ensure it can meet the 30-day payment terms and potential termination liquidated damages.
- Confirm the status of the Master Services Agreement, as the current Statement of Work is governed by attached terms until a Master Services Agreement is executed.